Dr. Gil Van Bokkelen is the Chairman and CEO of Athersys, Inc. (NASDAQ: ATHX), a biopharmaceutical company based in Cleveland, Ohio that was established in 1995. He has served as Chairman of the Board of Directors at Athersys since August, 2000, and as CEO since the company was formed. Since the company was founded, he has overseen the growth and development of the primary business operations at the company, and the transition from a venture backed start-up to a NASDAQ listed public company. Dr. Van Bokkelen received his Ph.D. in Genetics from Stanford University School of Medicine, and earned degrees in both Economics and Molecular Biology at the University of California at Berkeley.
In addition to his duties at Athersys, Dr. Van Bokkelen serves as the Chairman of the Board of Governors for the National Center for Regenerative Medicine (NCRM), a multi-institutional collaboration originally established as the Center for Stem Cells and Regenerative Medicine (CSCRM) in 2003 by the Cleveland Clinic, University Hospitals, Case Western Reserve University, the Ohio State University, and Athersys, Inc. From 2010 – 2012 he served as Chairman of the Alliance for Regenerative Medicine (ARM), a Washington D.C.-based non-profit organization whose mission is to educate key policy makers and others about the potential of regenerative medicine. He also serves as a member of the Biotechnology Industry Organization (BIO) Board, and has served on the board of other organizations as well. He has received numerous awards, including the Ernst & Young Entrepreneur of the Year Award, and the Blue Cross - SBN Visionary in Business Award.
3:15 PM–4:15 PM Jun 4, 2019